Luoxin Pharmaceuticals Group Stock Co.Ltd(002793)
Short form equity change report
Listed company: Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) listing place: Shenzhen Stock Exchange Stock abbreviation: Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) Stock Code: Luoxin Pharmaceuticals Group Stock Co.Ltd(002793)
Information disclosure obligor: ally bridge flagship LX (HK) Limited
Registered address: room 3 Fujian Nanping Sun Cable Co.Ltd(002300) 4, 30th floor, Gloucester building, landmark, 15 Queen’s road, Hong Kong
Mailing address: room 3 Fujian Nanping Sun Cable Co.Ltd(002300) 4, 30th floor, Gloucester building, landmark, 15 Queen’s road, Hong Kong
Nature of share change: decrease in shareholding
Date of signature: May 20, 2022
Statement of information disclosure obligor
The words or abbreviations mentioned in this part have the same meanings as those mentioned in the “interpretation” of this report. 1、 This report is prepared by the information disclosure obligor in accordance with laws, regulations and normative documents such as the securities law, the measures for the administration of acquisitions and the standards for content and format No. 15.
2、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules of the information disclosure obligor.
3、 In accordance with the provisions of the securities law, the measures for the administration of acquisitions and the standards for content and format No. 15, this report has fully disclosed the changes in shares in which the information disclosure obligor has an interest in Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) shares. As of the signing date of this report, except for the information disclosed in this report, the information disclosure obligor has not increased or reduced the shares with interests in Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) in any other way.
4、 This equity change is based on the information stated in this report. Except for the information disclosure obligor, no unit or individual has been entrusted or authorized to provide information not listed in this report and make any explanation and explanation to this report.
5、 There is no joint and several liability for the truthfulness, accuracy or misleading of the information recorded, omitted or disclosed in this report, and the individual is not jointly and severally liable.
catalogue
The disclosure obligor declares that 1 catalog 2 interpretation Section 1 Introduction to information disclosure obligors Section 2 purpose of equity change Section III equity change method 6 section IV trading of shares of Listed Companies in the first six months 8 section V other major matters Section VI documents for future reference 10 schedule thirteen
interpretation
In this report, unless the context otherwise requires, the following abbreviations have the following meanings:
This report refers to Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) simplified equity change report
Company, listed company and Luoxin pharmaceutical refer to Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) industry
Information disclosure obligor, ally refers to allybridge flagship LX (HK) Limited
Bridge
This equity change refers to the reduction of listed shares held by the information disclosure obligor
A share refers to domestic listed RMB ordinary shares
Stock exchange refers to Shenzhen Stock Exchange
The measures for the administration of acquisitions refer to the measures for the administration of acquisitions of listed companies
Content and Format Standard No. 15 refers to the content and Format Standard No. 15 – equity change report of information disclosure by companies offering securities to the public
RMB, 10000 yuan, 100 million yuan, yuan / share index RMB, 10000 yuan, 100 million yuan, RMB / share
Note: in this report, if the total is inconsistent with the mantissa of the sum of the sub item values, it is the mantissa caused by rounding.
Section I Introduction to information disclosure obligors
1、 Basic information of information disclosure obligor
(I) basic information
Company name ally bridge flagship LX (HK) Limited
Type private limited company
Registered address: room 3 Fujian Nanping Sun Cable Co.Ltd(002300) 4, 30th floor, Gloucester building, landmark, 15 Queen’s road, Hong Kong
Registration No.: 2482848
Director / authorized representative Peng Zhian, Pang, Andrew Chee on
Date of establishment: February 6, 2017
Business term not applicable
100 issued shares, US $1 per share, 1 ordinary share and 99 participating shares (without voting rights)
Business scope investment
Mailing address: room 3 Fujian Nanping Sun Cable Co.Ltd(002300) 4, 30th floor, Gloucester building, landmark, 15 Queen’s road, Hong Kong
Tel. + 85231219699
Ownership structure flagship lucky limited holds 1 ordinary share and 79 participating shares
Vibrant growth limited holds 20 participating shares
(II) basic information of directors, supervisors and senior managers of the information disclosure obligor
Serial number name position gender nationality long-term residence whether to obtain the right of residence in other countries or regions
1 Peng Zhian Pang, male director, UK, Hong Kong, China no
Andrew Chee On
2、 Information disclosure obligor’s equity shares in other domestic and overseas listed companies reach or exceed 5% of the issued shares of the company
As of the signing date of this report, the information disclosure obligor has no shares with interests in other domestic and overseas listed companies that reach or exceed 5% of the issued shares of the company.
Section 2 purpose of equity change
1、 Purpose of this equity change of the information disclosure obligor
Information disclosure obligors reduce their shares of listed companies due to their own development needs.
2、 Whether the information disclosure obligor intends to continue to increase or dispose of the shares of the listed company in the next 12 months
As of the signing date of this report, the information disclosure obligor intends to continue to dispose of the shares of the listed company in the next 12 months. In case of relevant equity changes in the next 12 months, the information disclosure obligor will timely perform the information disclosure obligations in accordance with the provisions of relevant laws.
Section III changes in equity
1、 The way of this equity change and the information disclosure obligor’s ownership of the interests of the listed company before and after the equity change
1. Overview of shareholding changes
On January 3, 2020, the company disclosed the report on major asset replacement and issuance of shares to purchase assets and related party transactions (Revised). According to relevant agreements, after the completion of the overall transaction scheme of major asset replacement, share transfer and issuance of shares to purchase assets, ally bridge holds 76271995 shares of the listed company, accounting for 5318300% of the total 143412507 shares of the listed company.
On April 7, 2020, the company disclosed the announcement on the implementation of major asset replacement and issuance of shares to purchase assets and related party transactions and listing of new shares. Calculated according to the total share capital of the listed company on March 24, 2020, the total number of shares of the company increased to 1445985238 after the registration and listing of new shares of the company’s major asset restructuring, and ally bridge held 76271995 shares of the listed company, The shareholding ratio is 5274742%.
On November 3, 2020, the company’s convertible bond “Dongyin convertible bond” stopped converting shares and was fully redeemed. The total number of shares of the company increased to 1458922600. Ally bridge held 76271995 shares of listed companies, the number of shares remained unchanged, and the shareholding ratio was passively diluted to 5227967%.
On November 18, 2020, the company’s equity incentive plan granted 830000 restricted shares for the first time, and the total number of shares of the company increased to 1467222600. Ally bridge held 76271995 shares of the listed company, the number of shares remained unchanged, and the shareholding ratio was passively diluted to 5198393%.
On August 16, 2021, the company’s equity incentive plan granted restricted shares for the first time. 3266680 shares were repurchased and cancelled due to the failure of the company’s performance to meet the assessment requirements and the resignation of some incentive objects. The total number of shares of the company was reduced to 1463955920. Ally bridge held 76271995 shares of listed companies, the number of shares remained unchanged, and the shareholding ratio increased passively to 5209993%.
On December 30, 2021, the company’s equity incentive plan granted restricted shares for the first time. Due to the resignation of some incentive objects, 266665 shares were repurchased and cancelled, and the total number of shares of the company was reduced to 1463689255. Ally bridge held 76271995 shares of listed companies, the number of shares remained unchanged, and the proportion of shares passively increased to 5210942%.
On March 3, 2022 and March 25, 2022, the company held the 19th meeting of the Fourth Board of directors and the 2021 annual general meeting of shareholders respectively, deliberated and adopted the proposal on terminating the implementation of the 2020 stock option and restricted stock incentive plan and canceling stock options and repurchasing and canceling restricted shares. The company terminated 4766655 restricted shares involved in the equity incentive plan, At present, relevant repurchase cancellation procedures are being handled. After the repurchase and cancellation of restricted shares under equity incentive, the total number of shares of the company will be reduced to 1458922600. If the number of shares of listed companies held by ally bridge remains unchanged, the shareholding ratio will increase passively.
2. Changes in equity this time
The reduction of the information disclosure obligor is implemented in the form of block trading through the securities trading system of Shenzhen Stock Exchange.
Before and after this equity change, the changes in the equity of the listed company held by the information disclosure obligor are as follows:
Name of shareholders before and after this transaction
Number of shares (shares) shareholding ratio number of shares (shares) shareholding ratio
Ally Bridge Flagship LX (HK) 76,271995 5210942% 73,184395 4999995%Limited
Total 762719955210942% 731843954999995%
2、 Description of whether there are any rights restrictions on the shares in which the information disclosure obligor has interests
As of the signing date of this report, the proposed change of the equity of the subject company held by the information disclosure obligor has no restrictions on rights such as pledge and freezing, and there is no restriction on transfer.
The number of shares involved in this equity change of the information disclosure obligor has strictly complied with the provisions on the reduction of shares held by shareholders, directors, supervisors and senior managers of listed companies, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board, and the implementation rules for the reduction of shares held by shareholders, directors, supervisors and senior managers of listed companies of Shenzhen Stock Exchange Regulations and normative documents.
Section IV trading of shares of Listed Companies in the first six months
The information disclosure obligor and its directors, supervisors and senior managers did not buy or sell the shares of the listed company through the centralized trading of the stock exchange six months before the change of equity.
Section V other major matters
As of the signing date of this report, the information disclosure obligor has truthfully disclosed the relevant information of this equity change in accordance with relevant regulations, and there is no other material information that should be disclosed in accordance with the application of law and in order to avoid misunderstanding of the report.
Section VI documents for future reference
1、 Documents for future reference
(I) company registration certificate of information disclosure obligor (copy);
(II) list of directors and main principals of the information disclosure obligor and their identity certificates (copies); 2、 Location of documents for future reference
This report and documents for future reference are placed in Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) , for investors’ reference. Investors can also visit the website of Shenzhen Stock Exchange (www.ssec. Com. CN.) Refer to the full text of this report.
Statement of information disclosure obligor
I (and the organization I represent) promise that the summary of this report does not exist
